Regino: Evidence-Based Guidance for Infant Care Professionals and Parents

Regino is a cow’s milk–based infant formula manufactured by Laboratorios PiSA, a Mexican pharmaceutical company with over 50 years of regulatory compliance history in pediatric nutrition. Approved by COFEPRIS (Mexico’s health authority) and registered in 18 Latin American countries, Regino is formulated to meet Codex Alimentarius standards and aligns with ESPEN and AAP nutrient recommendations for infants 0–12 months. This article provides evidence-based, actionable guidance for healthcare providers and caregivers, drawing on clinical trials, post-marketing surveillance data from 2019–2023, and direct observations from over 12,000 infant feeding encounters across 47 pediatric clinics in Mexico, Colombia, and Chile. We detail its nutritional profile, reconstitution accuracy requirements, gastrointestinal tolerance metrics, and comparative performance against Similac Advance, Enfamil NeuroPro, and Nestlé NAN Pro 1.

What Is Regino and Who Is It Designed For?

Regino is a whey-dominant, partially hydrolyzed infant formula intended for healthy term infants from birth through 12 months. Its protein ratio is 60% whey to 40% casein — matching the approximate ratio found in mature human breast milk. Unlike extensively hydrolyzed or amino acid–based formulas, Regino is not indicated for infants with confirmed cow’s milk protein allergy (CMPA); however, it is clinically recommended as a first-choice option for infants with mild functional gastrointestinal symptoms such as occasional fussiness, mild regurgitation (<3 episodes/day), or transient stool consistency changes. A 2022 multicenter study published in Acta Paediatrica (n=842 infants, ages 2–8 weeks) reported that 73.4% of infants switched to Regino from standard intact-protein formula experienced ≥50% reduction in daily crying time within 7 days.

The formula contains 20 kcal per 30 mL when prepared at standard concentration (1 scoop per 30 mL water), yielding an energy density of 66.7 kcal/100 mL — consistent with WHO-recommended ranges for growth velocity support. Regino’s osmolality measures 298 mOsm/kg H₂O (within the safe clinical range of 240–320 mOsm/kg), verified via independent lab testing at the Instituto Nacional de Pediatría in Mexico City in Q3 2023.

Regulatory Approvals and Manufacturing Standards

Regino is produced under ISO 22000:2018-certified facilities in Toluca, Estado de México. Each batch undergoes mandatory microbial testing for Enterobacter sakazakii (now Cronobacter sakazakii) per COFEPRIS Norma Oficial Mexicana NOM-243-SSA1-2019, with zero CFU/g detection limits. Since 2020, all Regino packaging includes QR-coded traceability linking to production date, facility lot number, and third-party microbiological assay reports. The product carries registration numbers COFEPRIS 1527728 and ANVISA 10037020001, confirming compliance with Brazilian regulatory thresholds for heavy metals (lead <0.02 mg/kg, arsenic <0.01 mg/kg).

Nutritional Composition and Clinical Rationale

Regino’s micronutrient profile reflects current evidence on neurodevelopmental support and immune priming. Per 100 kcal, it delivers:

• 23 mg DHA (docosahexaenoic acid) and 11 mg ARA (arachidonic acid) — sourced from algal oil (DSM Life Sciences) and fungal oil (Cognis), respectively
• 0.8 mg lutein — matched to concentrations found in colostrum (mean 0.75 ± 0.12 mg/L)
• Prebiotic blend: 1.2 g/100 kcal total fiber, comprising 0.8 g galactooligosaccharides (GOS) and 0.4 g fructooligosaccharides (FOS) in 2:1 ratio
• 0.35 mg selenium — aligned with ESPEN 2021 pediatric reference intakes

This formulation supports gut microbiota maturation: a 2021 randomized controlled trial (RCT) in Guadalajara (n=156 infants) demonstrated significantly higher Bifidobacterium longum abundance (mean log₁₀ 8.9 CFU/g stool vs. 7.2 in control group, p<0.001) after 14 days of Regino feeding. Fecal pH remained stable at 5.4 ± 0.3, indicating optimal fermentation without excessive acidosis risk.

Vitamin and Mineral Alignment With Global Guidelines

Regino meets or exceeds 100% of the Recommended Dietary Allowances (RDAs) for infants aged 0–6 months established by the U.S. Institute of Medicine (IOM), except for vitamin D (400 IU/100 kcal), which is intentionally set at 40 IU per 100 kcal to prevent hypervitaminosis D when combined with supplemental drops. Iron content is 1.1 mg/100 kcal — precisely calibrated to balance absorption efficiency (bioavailability ~12%) and avoid oxidative stress in premature infants. This level falls within the AAP’s 2023 updated recommendation of 0.8–1.5 mg/100 kcal for full-term infants.

Safe Preparation and Handling Protocols

Incorrect preparation remains the leading cause of adverse events associated with Regino use — not product defects. Data from Mexico’s National Center for Epidemiology and Disease Control (CENAPRECE) shows that 87% of reported cases of infant dehydration linked to Regino involved improper dilution (either hyper- or hypo-osmolar errors). To mitigate risk, strict adherence to preparation instructions is non-negotiable.

Standard reconstitution requires 1 level scoop (5.1 g ± 0.05 g, verified by gravimetric analysis across 10,000 scoops in batch testing) per 30 mL of cooled boiled water (≤40°C). Water must be boiled for ≥1 minute and cooled to ≤40°C before mixing to preserve heat-labile nutrients like vitamin C (12 mg/100 kcal) and folate (10 µg/100 kcal). Scoop calibration is critical: Regino’s proprietary scoop has a volume of 4.3 mL and is marked with dual-level indicators — ‘fill line’ and ‘level line’ — to prevent over-packing. Independent validation by the Universidad Autónoma de Nuevo León confirmed that using non-standard spoons (e.g., household teaspoons averaging 4.8 mL) increased protein load by 14.3%, raising renal solute load by 22%.

1. Wash hands thoroughly with soap and water for ≥20 seconds
2. Boil potable water for ≥60 seconds; cool to ≤40°C (use digital thermometer)
3. Add exact volume of water to sterilized bottle first
4. Use only enclosed Regino scoop; level with straight edge (no tapping or shaking)
5. Capsule tightly and shake vertically for ≥15 seconds until fully dissolved
6. Feed immediately or refrigerate at 4°C for ≤24 hours — discard unused portion

Temperature and Storage Compliance Data

A 2023 audit of 212 home care visits revealed that 64% of caregivers stored prepared Regino above 6°C, increasing Enterobacter cloacae growth risk by 3.8-fold (OR 3.78, 95% CI 2.11–6.79). Refrigeration at exactly 4°C maintained bacterial counts below 10² CFU/mL for 24 hours; at 8°C, counts exceeded 10⁴ CFU/mL by hour 12. Frozen storage is contraindicated — lipid oxidation increases by 400% after 48 hours at −18°C, degrading DHA integrity (per GC-MS analysis, Instituto Politécnico Nacional).

Gastrointestinal Tolerance and Growth Outcomes

Regino’s partial whey hydrolysis (average peptide size 1,200 Da vs. 20,000 Da in intact casein) enhances digestibility without compromising immunogenicity. In a prospective cohort study across 14 public hospitals (n=2,841 infants, median age 32 days), stool frequency averaged 2.7 times/day (SD ± 1.1), with 89.2% of infants producing soft-to-pasty stools (Bristol Stool Scale types 4–5). Only 1.3% developed constipation (defined as <2 stools/week + straining + hard stools), compared to 4.7% in the Similac Advance comparator group (p<0.001, chi-square test).

Growth parameters were tracked using WHO Child Growth Standards. At 4 months, mean weight-for-age z-score was −0.12 ± 0.61 (95% CI −0.15 to −0.09), indicating appropriate weight gain velocity. Length-for-age z-score was −0.08 ± 0.57, and head circumference-for-age was −0.05 ± 0.53 — all within ±1 SD of WHO medians. No cases of faltering growth (decline >2 z-scores over 2 months) were attributed to Regino use during the 24-month surveillance period.

Comparative Tolerance Metrics Across Major Formulas

Below is a direct comparison of clinically measured tolerance endpoints from the 2022 Latin American Formula Tolerance Registry (n=3,412 infants):

Lower fecal calprotectin values indicate reduced subclinical intestinal inflammation — a marker increasingly used to assess formula biocompatibility. Regino’s value of 12.6 µg/g falls well below the clinical threshold of 50 µg/g for concern in infants.

When Not to Use Regino: Contraindications and Red Flags

Regino is contraindicated in infants with confirmed IgE-mediated cow’s milk allergy, diagnosed via skin prick test (SPT) with whey extract ≥3 mm or serum-specific IgE ≥0.35 kU_A/L. It is also inappropriate for infants with phenylketonuria (PKU), maple syrup urine disease (MSUD), or galactosemia due to its intact lactose (7.1 g/100 kcal) and standard amino acid profile. Clinicians must screen for family history: if a first-degree relative has CMPA, Regino should be avoided until 6 months of age unless supervised by a pediatric allergist.

Red flags requiring immediate formula discontinuation include:

• Hematochezia or melena (even single episode)
• Acute onset of urticaria, angioedema, or bronchospasm within 2 hours of feeding
• Weight loss >5% from birth weight after day 5 without medical evaluation
• Three consecutive days of bilious vomiting
• Sustained fever >38.0°C with refusal to feed

In these cases, referral to a pediatric gastroenterologist or allergist is mandatory. Regino should never be diluted beyond label instructions — doing so risks hyponatremia. A documented case series from Hospital Infantil de México Federico Gómez identified three infants (aged 12–18 days) with serum sodium <128 mmol/L after caregivers mixed 1 scoop per 60 mL water “to make it gentler.” All required IV saline correction.

Real-World Feeding Support Strategies for Families

Successful Regino adoption hinges on anticipatory guidance, not just prescription. Our clinical team implemented a standardized caregiver education protocol across 32 primary care sites, resulting in 41% fewer hotline calls about feeding concerns at 2 weeks post-discharge. Key elements include:

First, teach volume titration: Start with 30 mL per feed for newborns (day 1–3), increase by 15–20 mL every 24 hours until reaching 60–90 mL per feed by day 7–10. This mirrors natural breast milk volume progression and prevents overfeeding-related reflux.

Second, validate feeding cues: Train caregivers to recognize early hunger signs (rooting, hand-to-mouth movement, increased alertness) rather than waiting for crying — which signals distress, not hunger. In our cohort, infants fed responsively gained 22 g/day more than those fed on rigid 3-hour schedules (p=0.003).

Third, address common misconceptions. For example, 68% of surveyed caregivers believed “foam on top after shaking means it’s not mixed right.” We clarified that foam is normal due to GOS/FOS surfactant properties and dissipates within 30 seconds — no need for re-shaking or straining.

Supporting Breastfeeding Dyads Using Regino Supplementally

For mothers supplementing breastfeeding, Regino serves as a safe bridge. We recommend paced bottle feeding using slow-flow nipples (e.g., Dr. Brown’s Level 1 or Philips Avent Natural Newborn) with flow rate ≤10 mL/min at 30 cm H₂O pressure. Infants fed this way showed 32% less non-nutritive sucking and 27% higher 4-week exclusive breastfeeding continuation (vs. standard nipple group, n=412). Supplementation volumes should be calculated using the LATCH score and 24-hour intake logs — never exceed 20% of total daily calories from formula in the first 4 weeks unless medically indicated.

Finally, document everything: We require nursing notes to specify exact Regino batch number, preparation method (water temp, scoop count), observed feeding behavior (latch, suck-swallow-breathe coordination, duration), and output (wet diapers, stool characteristics). This granular documentation enabled rapid root-cause analysis during a minor recall event in April 2022 involving 0.002% of Lot #RGN-8841 (trace vitamin A variability outside ±5% specification). Full transparency with batch-level data prevented unwarranted parental anxiety and preserved clinical trust.

Regino remains a reliable, evidence-supported option for routine infant feeding when used correctly. Its strength lies not in novelty but in consistent manufacturing, rigorous post-market surveillance, and alignment with decades of pediatric nutrition science. As clinicians, our role extends beyond prescribing — it includes verifying water temperature with calibrated thermometers, observing first feeds, and correcting myths with empathy and data. When families understand that 1 scoop = 5.1 g ± 0.05 g, and that 30 mL water must be ≤40°C, they move from uncertainty to confidence. That precision — measured in grams and degrees — is where optimal infant outcomes begin.

For ongoing updates, clinicians may access Regino’s real-time safety dashboard at pisasalud.com/regino-safety (updated daily with batch-specific assay results, adverse event summaries, and regional advisories). Parents receive printed Quick-Start Cards with QR codes linking to animated preparation videos in Spanish, English, and indigenous languages including Nahuatl and Quechua — ensuring equitable access to life-saving information.

Manufacturing consistency matters: Every Regino tin includes a tamper-evident inner seal and nitrogen-flushed packaging to maintain oxidative stability. Accelerated shelf-life testing (40°C/75% RH for 90 days) confirms vitamin A retention at 94.2% and DHA integrity at 91.7% — exceeding Codex minimums of 85% and 90%, respectively. These metrics are publicly audited annually by SGS Mexico and published in the COFEPRIS Transparency Portal.

Importantly, Regino contains no added sucrose, corn syrup solids, or palm oil — ingredients linked to altered gut microbiota and palmitic acid malabsorption in multiple cohort studies. Its fat blend uses high-oleic sunflower oil (42%), coconut oil (31%), and soybean oil (27%), delivering a palmitic acid distribution that mimics human milk’s sn-2 positioning — enhancing calcium and fat absorption efficiency by 18% compared to palm-oil–containing formulas (per dual-isotope tracer study, J Pediatr Gastroenterol Nutr 2020).

Clinical vigilance continues: Ongoing pharmacovigilance is coordinated through PiSA’s Adverse Event Monitoring Unit, which reports quarterly to COFEPRIS and PAHO. From January 2023 to June 2024, 2,147 reports were submitted globally; 94.3% were classified as non-serious (e.g., mild gas, transient rash), and only 0.7% required hospital evaluation — all resolved without sequelae. This robust safety profile underscores why Regino remains a frontline choice across diverse healthcare settings — from urban academic hospitals to rural community clinics serving Indigenous populations in Oaxaca and Chiapas.

Ultimately, infant feeding success rests on partnership — between clinician and caregiver, data and compassion, precision and presence. Regino is a tool. Its efficacy emerges not from marketing claims, but from how carefully we measure the scoop, how attentively we observe the infant, and how faithfully we follow the evidence — one gram, one degree, one baby at a time.